<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983888</url>
  </required_header>
  <id_info>
    <org_study_id>21-003887</org_study_id>
    <nct_id>NCT04983888</nct_id>
  </id_info>
  <brief_title>Obinutuzumab in Primary FSGS</brief_title>
  <official_title>A Single-center, Phase 2 Open-label Trial Evaluating the Efficacy and Safety of OBINUTUZUMAB in Treatment of Immunosuppression-dependent or Immunosuppression/Treatment-resistant Primary FSGS, or Contraindication/Patient Refusal to Take High Dose Corticosteroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Obinutuzumab in inducing&#xD;
      complete or partial remission of proteinuria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in proteinuria</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Measured using 24 hour urine collection reported in mg/24h</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission status at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>The number of subjects to reach either complete remission or partial remission at 12 months after infusion. Complete remission defined as proteinuria &lt; 0.3g/24 hrs. and no more than 20% decline in eGFR. Partial remission defined as 50% reduction in proteinuria and proteinuria &lt; 3.5 g/24hrs and no more than 20% decline in eGFR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission status at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>The number of subjects to reach either complete remission or partial remission at 12 months after infusion. Complete remission defined as proteinuria &lt; 0.3g/24 hrs. and no more than 20% decline in eGFR. Partial remission defined as 50% reduction in proteinuria and proteinuria &lt; 3.5 g/24hrs and no more than 20% decline in eGFR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum albumin</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Blood serum collected and reported in g/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAEs)</measure>
    <time_frame>24 months</time_frame>
    <description>Number of subjects to experience serious adverse events including serious infection defined as severe UTI or pyelonephritis, pneumonias or other systemic infections requiring hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria at 18 months</measure>
    <time_frame>18 months</time_frame>
    <description>Measured using 24 hour urine collection reported in mg/24h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Measured using 24 hour urine collection reported in mg/24h</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Primary Focal Segmental Glomerulosclerosis</condition>
  <arm_group>
    <arm_group_label>Primary Focal Segmental Glomerulosclerosis (FSGS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with immunosuppression-dependent or immunosuppression/treatment-resistant primary FSGS or contraindication/patient refusal to take high dose corticosteroids, will receive obinutuzumab 1 gram on day 1 and 1 gram on day 15, given intravenously and then an identical course at 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>1g IV on day one and 1 g IV on day 15, followed by identical course at month 6</description>
    <arm_group_label>Primary Focal Segmental Glomerulosclerosis (FSGS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years of age.&#xD;
&#xD;
          -  Biopsy proven Focal Segmental Glomerulosclerosis (FSGS) lesion&#xD;
&#xD;
          -  Foot process effacement ≥ 80% on electron microscopy.&#xD;
&#xD;
          -  Presence of nephrotic syndrome (proteinuria &gt; 3.5g/24hrs and serum albumin &lt; 3.5 g/dl)&#xD;
             prior to initiation of immunosuppressive therapy.&#xD;
&#xD;
          -  Resistant or dependent on therapy, including corticosteroids or calcineurin inhibitors&#xD;
             or who have failed rituximab. Patient who have contraindication to or refuse to take&#xD;
             high dose corticosteroids are allowed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Genetic or secondary forms of FSGS.&#xD;
&#xD;
          -  Hepatitis B, C or HIV positive.&#xD;
&#xD;
          -  Pregnant or breast-feeding.&#xD;
&#xD;
          -  Active infection.&#xD;
&#xD;
          -  Kidney transplant.&#xD;
&#xD;
          -  Anemia with Hgb &lt; 8.0 g/dL.&#xD;
&#xD;
          -  Thrombocytopenia with platelet count &lt; 100'000.&#xD;
&#xD;
          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or that may affect the&#xD;
             interpretation of the results or render the patient at high risk from treatment&#xD;
             complication.&#xD;
&#xD;
          -  Patients who have received cyclophosphamide in the last 6 months.&#xD;
&#xD;
          -  Patients who received rituximab previously with CD20 count of &lt; 5 cells/microliter at&#xD;
             the time of enrollment.&#xD;
&#xD;
          -  For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea)&#xD;
             or surgically sterile (absence of ovaries and/or uterus): agreement to remain&#xD;
             abstinent or use two adequate methods of contraception, including at least one method&#xD;
             with a failure rate of less than (&lt;) 1 percent (%) per year, during the treatment&#xD;
             period and for at least 18 months after the last dose of study drug.&#xD;
&#xD;
          -  For men: agreement to remain abstinent or use two adequate methods for contraception,&#xD;
             including at least one method with failure rate of less than 1% per year during the&#xD;
             treatment period and for at least 6 months (180 days) after the last dose of drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Fervenza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leah Majerus</last_name>
    <phone>507-266-4616</phone>
    <email>majerus.leah@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela Reinke</last_name>
    <phone>507-266-0956</phone>
    <email>reinke.angela@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Fernando Fervenza</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

